In the last years, major progress occurred in heart failure (HF) management. Quadruple
therapy is now mandatory for all the patients with HF with reduced ejection fraction. Whilst …

Heart has a recognized endocrine function as it produces several biologically active
substances with hormonal properties. Among these hormones, the natriuretic peptide (NP) …

Background The Mobile Health (mHealth) Technology for Improved Screening and
Optimized Integrated Care in atrial fibrillation (AF)(mAFA-II) cluster randomized trial …

Aim Mortality from acute myocardial infarction (AMI) has declined, increasing the pool of
survivors at risk of later development of heart failure (HF). However, coronary reperfusion …

Natriuretic peptides (NPs) are the principal expression products of the endocrine function of
the heart. They exert several beneficial effects, mostly mediated through guanylate cyclase …

Background Atrial fibrillation (AF) Better Care (ABC) pathway adherence is associated with
improved outcomes. Clinical trials have shown that non-vitamin K antagonist oral …

A time-to-first-event composite endpoint analysis has well-known shortcomings in evaluating
a treatment effect in cardiovascular clinical trials. It does not fully describe the clinical benefit …

Aims Carotid baroreflex activation therapy (BAT) restores baroreflex sensitivity and
modulates the imbalance in cardiac autonomic function in patients with heart failure with …

In the last years, major progress has occurred in heart failure (HF) management. The 2023
ESC focused update of the 2021 HF guidelines introduced new key recommendations …

Purpose: To systematically assess the efficacy and safety of sacubitril/valsartan (SV) by
comparison with angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor …